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Abstract
Ligand-induced homo- and hetero-dimer formation of ErbB receptors results in different biological outcomes irrespective of
recruitment and activation of similar effector proteins. Earlier experimental research indicated that cells expressing both
EGFR (epidermal growth factor receptor) and the ErbB4 receptor (E1/4 cells) induced E1/4 cell-specific B-Raf activation and
higher extracellular signal-regulated kinase (ERK) activation, followed by cellular transformation, than cells solely expressing
EGFR (E1 cells) in Chinese hamster ovary (CHO) cells. Since our experimental data revealed the presence of positive feedback
by ERK on upstream pathways, it was estimated that the cross-talk/feedback pathway structure of the Raf-MEK-ERK cascade
might affect ERK activation dynamics in our cell system. To uncover the regulatory mechanism concerning the ERK
dynamics, we used topological models and performed parameter estimation for all candidate structures that possessed ERK-
mediated positive feedback regulation of Raf. The structure that reliably reproduced a series of experimental data regarding
signal amplitude and duration of the signaling molecules was selected as a solution. We found that the pathway structure is
characterized by ERK-mediated positive feedback regulation of B-Raf and B-Raf-mediated negative regulation of Raf-1.
Steady-state analysis of the estimated structure indicated that the amplitude of Ras activity might critically affect ERK
activity through ERK-B-Raf positive feedback coordination with sustained B-Raf activation in E1/4 cells. However, Rap1 that
positively regulates B-Raf activity might be less effective concerning ERK and B-Raf activity. Furthermore, we investigated
how such Ras activity in E1/4 cells can be regulated by EGFR/ErbB4 heterodimer-mediated signaling. From a sensitivity
analysis of the detailed upstream model for Ras activation, we concluded that Ras activation dynamics is dominated by
heterodimer-mediated signaling coordination with a large initial speed of dimerization when the concentration of the ErbB4
receptor is considerably high. Such characteristics of the signaling cause the preferential binding of the Grb2-SOS complex
to heterodimer-mediated signaling molecules.
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Introduction
Overexpression or mutation of the ErbB receptor is closely
correlated with the incidence of various kinds of human cancer
[1,2]. The risk of cancer becomes especially elevated when
different ErbB receptors are co-expressed [3,4]. This phenomenon
is also confirmed at the cellular level, where transformation of cells
occurs when different ErbB receptors are co-expressed in the same
cells [5–7]. However, this cellular transformation mechanism has
not been identified because an investigation of the primary
interaction of adaptor proteins following kinase activation induced
by growth hormones results in relatively small differences in
protein binding patterns for cells expressing either single- or
multiple-species of ErbB receptors [8–10]. For example, EGF
(epidermal growth factor)-stimulated EGFR (epidermal growth
factor receptor) in ErbB4 co-expressing cells essentially interacts
with adaptor and effector proteins such as growth factor receptor-
bound protein2 (Grb2), Src homology and collagen domain
protein (Shc), the p85 subunit of phosphatidylinositol 39-kinase
(PI3K), Cbl and phospholipase Cc (PLCc) in a manner that is
similar to EGF-stimulated cells solely expressing EGFR [8,10].
Therefore, the increase in biological response elicited by the
coexpression of ErbB receptors cannot be solely explained by
specific protein interactions induced by each receptor. Recently, it
was understood that quantitative (strength and duration of
activities of the pathways) rather than qualitative (e.g. regulation
of different pathways) differences between signaling pathways may
largely account for dissimilar biological responses [11]. This
explanation may be relevant to a general investigation of factors
determining ligand-specific or receptor-specific signal transduction
pathways when considering the fact that mammalian cells share
almost the same sets of signaling components [12–14].
Several studies indicated that signal amplitude and duration are
temporally modulated by cross-talk between two pathways (e.g.
Raf inhibition by Akt) [14,15] and inhibitory feedback from ERK
to Grb2-SOS complex formation [16,17] and Raf [18–20].
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ovary (CHO) cells expressing both EGFR and ErbB4 receptors
(E1/4 cells) induced specific B-Raf and higher ERK activation
than cells solely expressing the EGFR receptor (E1 cells) and
induced cellular transformation [21]. It is therefore understood
that regardless of the same primary recruitment of effector
proteins to each ErbB receptor dimer, the cells induce different
structures of downstream regulatory pathways and that such
differences might cause a change in the kinase activity level in
relation to the cell fate determination process.
The aim of the present study is to give a mechanistic insight into
how E1/4 cells induce a higher amplitude of ERK activity than E1
cells and how B-Raf is involved in ERK activation in an E1/4 cell-
specific manner. Our experimental data showed that the inhibiting
kinase activity of MEK (MAP kinase kinase) on ERK lowered the
MEK response with EGF, indicating that there might exist positive
feedback by ERK somewhere within upstream pathways.
Furthermore, there are increasing reports of cross-talk between
Raf-1 and B-Raf pathways [18–20,22,23]. However, the pathway
structure of feedback/cross-talk in the MAPK cascade is not clear
in our CHO cell lines. Therefore, we estimated the structure based
on model parameter estimation examining which structures could
reliably reproduce the experimental data with respect to the signal
amplitude and duration of the signaling molecules. Although a
main structure of MAPK cascade was originally analyzed by
Heinrich et al. [24] and Huang et al. [25], we are the first to apply
the topological modeling to CHO cells by adding cross-talk and
feedback to explain ERK activation dynamics. As a result, we
specified a structure that possesses both negative cross-talk
regulation by B-Raf to Raf-1 and positive feedback by ERK to
B-Raf. The steady-state analysis of the estimated pathway
structure of the Raf-MEK-ERK cascade indicated that the
amplitude of Ras activity might critically affect ERK activity
through ERK-B-Raf positive feedback coordination with sustained
B-Raf activation in E1/4 cells. On the other hand, it was shown
that the amplitude of Rap1 activity might be less influential on
ERK activity. Accordingly, we further investigated differences in
amplitude of Ras activity in ErbB signaling pathways using a
detailed upstream model modified from Kholodenko’s [26]. The
sensitivity analysis indicated that the initial reaction velocity of
EGFR/ErbB4 receptor heterodimerization might be considerably
higher than that of EGFR homodimerization, and as a result, the
Grb2-SOS complex preferentially binds to the activated hetero-
dimer rather than the activated homodimer. Finally, we concluded
that the amplitude of Ras activity becomes more potent under
high expression of the ErbB4 receptor in E1/4 cells.
Results
Estimation of the feedback and cross-talk structure of the
Raf-MEK-ERK cascade in CHO cells using a mathematical
model
We first experimentally investigated the presence of feedback
regulation by ERK on upstream signal transduction pathways
using the MEK inhibitor. The MEK-mediated activation of ERK
through phosphorylation of ERK threonine/tyrosine residues has
been well established. The inhibition of kinase activity of MEK on
ERK and subsequent measurement of MEK phosphorylation
represents one approach that could be used to evaluate the effect
of ERK-mediated feedback on the upstream pathways. U0126 is a
selective inhibitor of MEK and can therefore be used to block the
phosphorylation of ERK by MEK [27]. Results indicated that
EGF-induced MEK activity decreased when ERK activation was
inhibited through the use of U0126 in both E1 and E1/4 cells
(Figure 1) (The Western blot data relating to ERK activity
following U0126 use is provided in Figure S1). This fact implied
positive feedback regulation by ERK on upstream molecules,
although the feedback point was not clear. Additionally, there is a
possibility of cross-talk between Raf isoforms, which has been
reported in many cell lines [20,22,23]. In order to determine the
structure of feedback/cross-talk in CHO cells, we carried out
topological modeling of the central Raf-MEK-ERK cascade
(Figure 2). We began by using the main structure of the MAPK
cascade (steps 1–11) originally given by Heinrich et al. [24], and
then included feedback (steps 13, 15, 16, 18), cross-talk (steps 12,
14, 17, 19), and dual phosphorylation of ERK (steps 8–11)
components [28–30]. Detailed information pertaining to model
construction is summarized in Materials and Methods. We
assumed that the structure and kinetic parameters are identical
for E1 and E1/4 cells, whereas time courses relating to Ras- and
Rap1-GTPs, which represent inputs of the cascade, can differ.
Moreover, we assumed that the effect of feedback regulation by
ERK on upstream pathways can be approximated by the effect on
Raf activity. For instance, suppose that SOS (Son of Sevenless
homologue protein) is negatively regulated by ERK [16], and the
down-regulation of SOS activity reduces Raf-1 activity via the
down-regulation of Ras. Raf-1 activation is then modeled with
ERK negative feedback in our topological model. Similarly, we
assumed cross-talk regulation between Raf-1 and B-Raf.
Steps 12–19 were included as possible candidates of feedback/
cross-talk connections that should be determined. The number of
possible structures regarding cross-talk and feedback is 81 (=3
4)
since there can be three kinds of regulation (positive, negative, or
not present) for each of four interactions, ERK to Raf-1 (steps 13
and 15), ERK to B-Raf (steps 16 and 18), Raf-1 to B-Raf (steps 17
Figure 1. The effect of MEK inhibitor U0126 on MEK
phosphorylation in E1 and E1/4 cells. Serum-starved E1 and E1/4
cells were incubated with 10 nM EGF for the indicated time period with
or without pretreatment of 200 nM U0126. MEK phosphorylation was
analyzed by Western blot with the corresponding anti-phospho-specific
MEK antibodies (upper panel), and then reblotted with an anti-MEK
antibody (lower panel). (A) Western blot for E1 cells. (B) Western blot for
E1/4 cells. Data show a representative figure of three independent
experiments. Quantified data are available in Table S1 (no. 3).
doi:10.1371/journal.pone.0001782.g001
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the candidates, we took into account the experimentally observed
positive feedback by ERK (Figure 1). Moreover, for simplicity we
excluded the situation involving the coexistence of both Raf-1
regulation by B-Raf and B-Raf regulation by Raf-1. These
constraints narrowed down the 81 possible candidates to 29
structures that contain direct/indirect positive feedback by ERK
to B-Raf (nos. 1–10), Raf-1 (nos. 11–20), and both B-Raf and Raf-
1 (nos. 21–29) (Figure 3).
For each of the 29 structures, we estimated the model
parameters to reproduce the experimental data. Here, we
employed the hypothesis that appropriate structures could explain
experimental results using suitable kinetic parameters. Addition-
ally, we also hypothesized that a biological pathway is robust
against small parameter changes, and that the parameter should
therefore be easily searched when the pathway structure is solid.
For parameter estimation, we prepared 29 ODE (ordinary
differential equation) models and six time-course datasets each
from the Western blot analyses of E1 and E1/4 cells (Table 1,
nos. 1–3). Additionally, we developed an input signal generator to
reproduce the experimental data relating to Ras- and Rap1-GTPs
(Figure 4 and Table 1, nos. 4 and 5). Detailed information relating
to the input signal generator is provided in Text S1, Tables S2, S3,
S4 and Figures S2 and S3. Moreover, we experimentally measured
the time course of B-Raf activation (Table 1, no. 6), which showed
sustained activation, for validation of the model. The procedure of
model selection based on parameter estimation is provided in
Materials and Methods.
Application of the aforementioned selection process yielded two
structures (numbers 4 and 29) that satisfied all criteria for model
selection. In fact, the simulation results were quite similar for the
two structures (see Figure 5A for the number 4 structure and
Figure S4 for all structures). Interestingly, both structures possess
positive feedback by ERK to B-Raf and negative cross-talk
regulation by B-Raf to Raf-1, and the difference between the two
structures being the absence or presence of ERK-mediated
positive feedback regulation of Raf-1. However, we found that
the ERK-mediated regulation of Raf-1 in number 29 structure was
negligible since the maximum velocity was markedly smaller than
that determined for Ras-GTP, indicating that the number 29
structure was essentially the same as the number 4 structure.
Therefore, we concluded that the structure of the Raf-MEK-ERK
cascade in E1 and E1/4 cells might be characterized by the
number 4 structure, which possesses negative cross-talk regulation
by B-Raf to Raf-1 and positive feedback by ERK to B-Raf (steps
14 and 16). The model description and kinetic parameters
pertaining to the number 4 structure are provided in Tables S5
and S6.
Characteristics of the estimated pathway structure of the
Raf-MEK-ERK cascade
In order to investigate the characteristics of the identified
pathway structure, we next carried out a steady-state analysis for
ERK and B-Raf responses under the constant inputs of Ras- and
Rap1-GTPs (Figures 5B and 5C). As a result, we found that ERK
activity increased with a steep slope along with the input level of
Figure 2. Topological model of the Raf-MEK-ERK cascade in CHO cells. The inputs of the Raf-MEK-ERK cascade are the activated forms of Ras
and Rap1, Ras-GTP and Rap1-GTP. The output is the doubly phosphorylated ERK, ERKPP. Steps 1–11 are the fixed part of the cascade, whereas steps
12–19 are possible cross-talk/feedback connections to be determined. The selected pathways were steps 14 and 16 (red arrows). Numbers shown
correspond to the kinetic equations in Table S5.
doi:10.1371/journal.pone.0001782.g002
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can stabilize the promotion of ERK activity, but be insensitive to
that of Rap1-GTP (Figure 5B). This indicated that ERK activity
might be regulated predominantly by Ras activity rather than
Rap1 activity in this pathway structure. Interestingly, this
conclusion was also true for B-Raf activity (Figure 5C), although
B-Raf can also be regulated by Rap1-GTP. If this is the case,
Rap1 activity would be less influential on ERK activity. In order to
confirm the lesser impact of Rap1 activity on ERK activity, we
compared ERK activity 5 min after 10 nM EGF treatment in the
presence or absence of the PLCc inhibitor U73122, which can
indirectly suppress Rap1 activity in CHO cells (Tables 1, no. 7)
[21]. U73122 showed less effect on ERK activity both in E1 and
E1/4 cells, and is consistent with the above-mentioned perspective
based on steady-state analysis.
As shown in Figure 4A, the peak level of Ras activation in E1/4
cells was considerably higher than that of E1 cells. We marked the
points at which the amplitude of ERK and B-Raf activity would be
Figure 3. The 29 pathway structures that possess positive feedback by ERK to Raf. The 29 pathway structures that possess positive
feedback by ERK to Raf isoforms can be classified into three types of regulation depending on which isoform is positively regulated: B-Raf (nos. 1–10),
Raf-1 (nos. 11–20), or both B-Raf and Raf-1 (nos. 21–29). The symbol for MEK is omitted here for clarity.
doi:10.1371/journal.pone.0001782.g003
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(Figures 5B and 5C) to determine the extent to which the
differences impact on ERK and B-Raf activity. Since the input
level of Rap1-GTP was not sensitive to ERK activity, we placed
symbols at a zero input level of Rap1-GTP for clarity. Notably, the
peak activity of Ras-GTP in E1/4 cells was placed at the upper
level of ERK activity over the steep slope in comparison with that
of E1 cells, which was placed at the lower level (Figure 5B).
Therefore, we concluded that the experimentally observed
difference in amplitude of ERK activity was mainly caused by
differences in amplitude of Ras activity between E1 and E1/4
cells. Unlike the case of ERK, the peak activity of Ras-GTP in E1
cells was placed at the upper part of the slope of the B-Raf activity
profile (Figure 5C); the amplitude of B-Raf activity is therefore
quite close to that for E1/4 cells. Furthermore, we investigated
ERK and B-Raf activities that would be induced by input levels
equivalent to Ras activity 30 min following EGF treatment as
depicted in Figure 4A. We found that B-Raf activity at 30 min
differed markedly between E1 and E1/4 cells (Figure 5C), whereas
ERK activity returned to considerably lower levels in both cell
lines (Figure 5B). This implies that B-Raf activity would be
sustained for a greater period of time in E1/4 cells than in E1 cells.
Taken together, these results indicate that the characteristics of the
Raf-MEK-ERK cascade are determined mainly by the amplitude
of Ras activity and not Rap1 activity. Additionally, differences in
the peak level of ERK activity between E1 and E1/4 cells might
result from differences in Ras activation amplitude coordination
with E1/4 cell-specific sustained B-Raf activation.
Detailed upstream model of EGFR/ErbB4 heterodimer-
mediated Ras activation
Many studies revealed that ErbB receptor-mediated Ras
signaling is deeply involved in ERK activation upon EGF
Figure 4. Time courses of Ras- and Rap1-GTPs. The input signal generator reproduced the time-course data of Ras- and Rap1-GTPs with 10 nM
EGF. (A) Normalized time-course data of Ras-GTP. (B) Normalized time-course data of Rap1-GTP. The graphs represent the normalized activity of Ras-
and Rap-1 GTPs in which the data are divided by the value for E1/4 cells at 1 min. Blue and red lines correspond to simulation data for E1 and E1/4
cells, respectively. The filled squares and circles correspond to experimental data concerning E1 and E1/4 cells, respectively.
doi:10.1371/journal.pone.0001782.g004
Table 1. Time-course data from Western blot analysis.
No Molecules Inhibitor data points (min) treated cell lines Intended purpose
1 phosphorylated ERK - 0, 1, 2, 3, 5, 10, 20, 30 E1, E1/4 parameter estimation for the topological model
2 phosphorylated MEK - 0, 1, 2, 3, 5, 10, 30 E1, E1/4 parameter estimation for the topological model
3 phosphorylated MEK U0126 0, 1, 2, 3, 5, 10, 30 E1, E1/4 parameter estimation for the topological model
4 Ras-GTP - 0, 1, 2, 5, 10, 30 E1, E1/4 training data for the input signal generator and the detailed upstream
model
5 Rap1-GTP - 0, 0.5, 1, 2, 3, 5, 10, 30 E1, E1/4 training data for the input signal generator and the detailed upstream
model
6 activated B-Raf - 0, 1, 2, 5, 10, 30 E1/4 additional test for the topological model
7 phosphorylated ERK U73122 5 E1, E1/4 inhibitor test for the topological model
8 phosphorylated EGFR - 0, 1, 2, 10, 30 E1, E1/4 parameter estimation for the detailed upstream model
9 phosphorylated ErbB4 - 0, 1, 2, 10, 30 E1/4 parameter estimation for the detailed upstream model
10 phosphorylated Shc - 0, 1, 2, 5, 10, 30 E1, E1/4 parameter estimation for the detailed upstream model
The experimental protocol is summarized in Materials and Methods. The quantified data are shown in Table S1. All experiments were performed using 10 nME G F .
doi:10.1371/journal.pone.0001782.t001
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which results in Ras activation [30,32], might be regulated by
mechanisms that differ between E1 and E1/4 cells [33]. However,
the detailed mechanism concerning EGFR/ErbB4 heterodimer-
mediated signaling is still unclear. In the previous section we
demonstrated that differences in amplitude of ERK activity
between the two cell lines might be caused predominantly by
different Ras activities independently of Rap1 activation dynam-
ics, where we assumed that the pathway structure and kinetic
parameters of the central Raf-MEK-ERK cascade were the same.
We therefore constructed a detailed upstream model of EGFR/
ErbB4 heterodimer-mediated Ras activation to predict how
differences in amplitude of Ras activity between E1 and E1/4
cells can be caused (Figure 6). We assumed that one of the crucial
factors is the presence of the ErbB4 receptor in the pathways,
implying that homodimer-mediated pathways (steps 1–12, the left
box in Figure 6) are common in the two cell lines and that
heterodimer-mediated pathways (steps 14–22, the right box in
Figure 6) are E1/4 cell-specific. For a simulation of E1 cells, the
concentration of the ErbB4 receptor was set to zero. Then, steps
Figure 5. The time-course simulation and steady-state responses of the number 4 structure. (A) The simulation results are shown with
the corresponding experimental data. Filled squares and circles indicate experimental data relating to E1 and E1/4 cells, respectively. Blue and red
lines indicate the simulation data relating to E1 and E1/4 cells, respectively. The x-axis represents time (min) and the y-axis activation (% of total
protein). In (B) and (C) the steady-state responses of ERK and B-Raf activity for the selected pathway structure are shown. The input signal levels of
Ras- and Rap1-GTPs to the Raf-MEK-ERK cascade characterized by the number 4 structure were changed in the range 0.1 to 2.0. The simulation for
each input level was then ran for 100,000 sec to approximate the steady-state values where the activity of all molecules hardly moved at about the
termination time of the simulation. (B) 3-D graph of steady-state ERK activity. (C) 3-D graph of steady-state B-Raf activity. The colors of the graphs
indicate activation (% of total protein). Open and filled circles correspond to the activation level induced by the input level equivalent to the peak
level of Ras-GTP in E1 and E1/4 cells, respectively. Similarly, open and filled squares correspond to the activation level induced by the input level
equivalent to the activity level 30 min following EGF stimulation of Ras-GTP in E1 and E1/4 cells, respectively.
doi:10.1371/journal.pone.0001782.g005
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E11P_ShcP_GS (step 12), otherwise control was achieved through
E11P_ShcP_GS and E14P_ShcP_GS (steps 12 and 22). Steps 1–
11, which include Shc recruitment to the receptor, binding to the
Grb2-SOS complex and receptor internalization, were adopted
from the earlier study [26]. However, those were re-simplified to
maintain the essential dynamics of the pathway [29]. Our
experimental data indicated that the signal amplitude of EGFR
phosphorylation was similar in E1 and E1/4 cells although the
dynamics seemed to differ (Figure 7A), while the amplitude and
dynamics of Shc phosphorylation were very different (Figure 7C).
Therefore, we hypothetically introduced the steps 14–22 in order to
take into account the effect of ErbB4 receptor-mediated signaling on
Shc and Ras regulation. Kinetic parameters were also estimated
using GLSDC (Genetic Local Search with distance independent
Diversity Control) by comparing the experimental data (Table 1,
nos. 4, 8–10) with simulated values (See Materials and Methods for
parameter estimation of the upstream model). The model descrip-
Figure 6. Detailed upstream model of EGFR/ErbB4 heterodimer-mediated Ras activation. The pathways in the left and right boxes are
mediated by the EGFR homodimer and the EGFR/ErbB4 heterodimer, respectively. Ras activation is regulated by these two pathways via steps 12 and
22. When performing parameter estimation of total concentrations and kinetic parameters for the E1/4 cells, all parameters were estimated. On the
other hand, the concentration of the ErbB4 receptors was set to zero for E1 cells, while other unknown parameters were considered to be identical as
those for the E1/4 cells. Numbers shown correspond to the kinetic equations in Table S7.
doi:10.1371/journal.pone.0001782.g006
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the simulation model was used to examine the effect of a 10 nM
EGF perturbation on E1 and E1/4 cells, the model reasonably
reproduced a similar signal amplitude of EGFR phosphorylation,
different amplitude and dynamics of Shc phosphorylation, different
amplitude of Ras activation, and transient dynamics of ErbB4
phosphorylation in E1/4 cells (Figure 7).
Next, we investigated the effect of ErbB4 receptor-mediated
pathways on Ras activation. To this end, we varied the
concentration of the ErbB4 receptor from about 100% of the
total ErbB4 receptors in E1/4 cells to about 0% (Figures 8 and 9).
The model with 0% ErbB4 receptors corresponds to the E1 cell
model. As the abundance of ErbB4 receptors increased, the peak
level of activation of E14P_ShcP_GS increased with a steep slope,
whereas that of E11P_ShcP_GS decreased (Figure 8). Further-
more, we found that the peak level of E14P_ShcP_GS was much
greater than that of E11P_ShcP_GS, especially for higher
concentrations of the ErbB4 receptor. Therefore, the peak level
of Ras activation might be critically affected by the concentration
of ErbB4 receptors through E14P_ShcP_GS (step 22 in Figure 6)
rather than E11P_ShcP_GS (step12). Figure 9 shows the time-
course patterns of signaling molecules in this sensitivity analysis.
The change in peak level of E14P_ShcP was also affected by the
concentration of ErbB4 receptors as well as E14P_ShcP_GS
(Figures 9B and 9D), although E11P_ShcP was not sensitive to
such changes (Figures 9A). However, the peak level of
E11P_ShcP_GS became quite small at around a 100% concen-
tration of ErbB4 receptors despite such insensitivity (Figure 9C)
compared to that of E14P_ShcP_GS (Figure 9D). E11P_ShcP and
E14P_ShcP share the interaction partner, the GS (Grb2-SOS)
complex. In addition, the initial reaction velocity of E14P_ShcP
was faster than that of E11P_ShcP at higher concentrations of the
ErbB4 receptor (60–100%) (Figures 9A and 9B). Therefore, GS
might preferentially bind to E14P_ShcP rather than E11P_ShcP.
These results as a whole indicate that the concentration of the
ErbB4 receptor in our detailed model might be quite important for
the considerably strong Ras activation observed in E1/4 cells,
where the ErbB4 receptor-mediated signaling pathway can
dominate Ras activation dynamics.
Discussion
Cells co-expressing different ErbB receptors tend to undergo
cellular transformation more frequently than cells expressing a single
type of the receptor [3–6]. Our earlier study reported that cellular
transformation occurs only in cells co-expressing both EGFR and
ErbB4 receptors, but not in cells expressing only EGFR or ErbB4,
suggesting that different cell fates might originate from the
enhancement of ERK activation mediated by E1/4 cell-specific B-
Raf activation, although homo- and hetero-dimers could recruit
Figure 7. Time-course activity of signaling molecules with 10 nM EGF in ErbB signaling. The responses of the signaling molecules during
30 min are plotted with the corresponding experimental data listed in Table 1 (nos. 4 and 8–10). (A) Phosphorylated EGFR in E1 and E1/4 cells,
respectively. (B) Phosphorylated ErbB4 receptor in E1/4 cells. (C) Phosphorylated Shc in E1 and E1/4 cells, respectively. (D) Ras-GTP in E1 and E1/4
cells, respectively. Blue and red lines indicate simulation data for E1 and E1/4 cells, respectively, and filled squares and circles indicate experimental
data E1 and E1/4 cells, respectively. Graphs represent activity (% of total protein).
doi:10.1371/journal.pone.0001782.g007
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question is raised concerning how the signal amplitude of the signal
transduction pathway and the cell-specific activation were controlled
in the ErbB receptor co-expression system.
Since the Raf-MEK-ERK cascade is considered a core compo-
nent of the signaling network, and Raf isoforms are key downstream
targets of ErbB receptors [34], it is reasonable to assume that the
Raf-MEK-ERK cascade consists of the same structure in E1 and
E1/4 cells. However, since the regulation of Raf isoforms is complex
and cell-specific [12,18,22,35], we initially estimated the feedback/
cross-talk structure of the cascade using topological modeling. In
addition to the 6 measured quantities (Table 1, nos. 1–3), the time-
course inputs of Ras- and Rap1-GTPs were also utilized as
additional constraints in the determination (Table 1, nos. 4 and 5).
The time-course patterns of Ras- and Rap1-GTPs (Figure 4) were
sufficiently different to allow for a determination of parameters
differentiating the Raf-1 and B-Raf pathways. Moreover, given the
benefits of simplified modeling using minimal variation of feedback/
cross-talk connections, we were able to arrive at a structure that
possessed negative cross-talk regulation of Raf-1 by B-Raf and
positive feedback by ERK to B-Raf. Since an earlier study indicated
that ERK-induced phosphorylation of B-Raf on Thr
753 promoted
the disassembly of Raf-1/B-Raf heterodimer, followed by low kinase
activity of Raf-1 in COS-1 cells [23], this result might support our
estimated pathway structure. Activation and deactivation of Raf
isoforms are tightly regulated, although the mechanisms involved in
this regulation are not fully known. There are reports that B-Raf is
activated by Ras and Raf-1 requires additional mediators [35], while
90% of ERK activity is dependent on B-Raf activity in nerve growth
factor-induced PC12 cells [12]. On the other hand, contradictory
studiesshowed thatRaf-1 isactivatedbyits ownfeedbackfromERK
[18] and that Raf-1 activates B-Raf in a Ras-dependent manner
[22]. Our simulation analysis only explains topological regulation of
time-course events, not the molecular functions. However, the
ligand-stimulated Raf activation and deactivation mechanism
seemed to involve cell- and ligand type-specific complex events.
Therefore, our pathway estimation indicated that one can estimate
the hidden regulatory pathways using mathematical modeling. In
fact, it was reported that the feedback structure of the MAPK
network can be either negative or positive depending on the kind of
ligand, EGF or NGF, in PC-12 cells [36].
It is well known that ligand-induced activity of signaling proteins
in a MAPK cascade can be promoted in an ultrasensitive manner
depending on the pathway structure and kinetic parameters
[24,25]. From the steady-state analysis of ERK and B-Raf activity
response to the constant input of Ras- and Rap1-GTPs, we found
that ERK and B-Raf activity was steeply elevated along with the
input level of Ras-GTP in the selected pathway structure, although
there was no sensitivity to Rap-1. This lesser effect of Rap1 on
ERK activity was also confirmed by Western blot analysis of ERK
activation by suppressing the PLCc-Rap1 pathway using the
specific PLCc inhibitor. The role of Rap1 in Ras-mediated
signaling is still unclear. Rap1 might be implicated in both
negative and positive control of Ras-mediated signaling depending
on the kinds of ligand and cell lines [37,38–40]. However, our
results might be consistent with the earlier results of Zwartkrius et
al. [41] in which it was shown that Rap1 did not affect ERK
activation in Rat-1 cells.
Our earlier study showed that E1/4 cells induced specific B-Raf
and higher ERK activation upon EGF stimulation than E1 cells,
followed by cellular transformation [21]. From the steady-state
analysis, we concluded that the peak level of Ras activity in E1/4
cellswassufficientlyhightoinducetheultrasensitiveERKactivation.
On the other hand, activity inE1 cells is near the bottom of the slope
ofthe Ras-ERK steady-state response curve,suchthat the amplitude
ofERKactivityinE1cellsbecameconsiderablylow.In addition, the
B-Raf steady-state response induced by the peak level of Ras activity
is similar and high in E1 and E1/4 cells, but considerably different
when evaluating Ras activity 30 min after EGF stimulation. Such a
difference might cause the different B-Raf activation dynamics upon
EGF stimulation, which are sustained in E1/4 cells and transient in
E1 cells. The sustained B-Raf activation can then stabilize the
promotion of ERK activity through the ERK-B-Raf positive
feedback loop in E1/4 cells.
The mechanism of Ras activation dynamics has been
investigated in many studies using mathematical modeling
[26,29,42]. However, less is known about the effect of hetero-
dimerization on signal transduction pathways. In the present
study, we found that the amplitude of Ras activity becomes more
potent as the concentration of ErbB4 receptors increases in E1/4
cells. An earlier study revealed that co-expression of EGFR with
ErbB2 or ErbB3 biases signaling to the cell surface and retards
signal down-regulation, followed by prolonged signaling of
downstream molecules [43]. Unlike the ErbB1-3 system, we
speculated that the initial reaction velocity of EGFR/ErbB4
receptor heterodimerization might be important and considerably
higher than that of EGFR homodimerization in our CHO cells. In
fact, the critical parameter in determining signal efficacy for the
EGFR homodimer-mediated signal transduction system is the
initial velocity of receptor activation [42]. We have reached a
similar conclusion with EGFR/ErbB4 heterodimer-mediated
signaling, but here we insisted that the initial velocity of
heterodimerization might be more effective for Ras activation
dynamics than that of the homodimer. If we follow the ODEs of
the detailed upstream model, the concentration of dimers, E11
Figure 8. Effect of ErbB4 receptor concentration on
E11P_ShcP_GS and E14P_ShcP_GS. The two complexes
E11P_ShcP_GS and E14P_ShcP_GS in Figure 6 regulate Ras activity.
The solid and dashed lines represent the change in peak activity (%) of
E14P_ShcP_GS and E11P_ShcP_GS, respectively, following 10 nM EGF
treatment and depending on the concentration of ErbB4 receptors in
the detailed upstream model, respectively. The 0% ErbB4 receptor
concentration (E4=0) is regarded as representing E1 cells, while the
100% level (E4=1.0) represents E1/4 cells.
doi:10.1371/journal.pone.0001782.g008
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d E11 ½ 
dt
~k2 EGF E1 ½ 
2z{ k{2 E11 ½  {k3 E11 ½  zk{3 E11P ½  Þ f
zk4 E11P ½  = k{4z E11P ½  ðÞ g
ð8Þ
d E14 ½ 
dt
~k14 E4 ½  EGF E1 ½  z{ k{14 E14 ½  {k15 E14 ½  f z
k{15 E14P ½  Þ zk16 E14P ½  = k{16z E14P ½  ðÞ g
ð9Þ
Since the initial concentrations of E11, E11P, E14 and E14P are
equivalent to zero, the initial velocities of E11 and E14 are
dominated by the first terms. Therefore, in the range
EGF E1 ½  v
k14 E4 ½ 
k2
ð10Þ
the reaction velocity of E14 becomes higher than that of E11,
followed by the difference in the initial reaction velocity. Again, it
should be noted that such a range would be wider when the
concentration of ErbB4 receptors is high.
Figure 9. Effect of ErbB4 receptor concentration on the time-course pattern. The concentration of the ErbB4 receptor (E4) was changed
from 100% of the total ErbB4 receptors (E4=1.0) in E1/4 cells to 0% (E4=0.0). Figures demonstrate time-course patterns of signaling molecules in
relation to the abundance of the ErbB4 receptor in silico. (A) and (C) The signaling molecules E11P_ShcP and E11P_ShcP_GS in EGFR homodimer-
mediated pathways, respectively. (B) and (D) The signaling molecules E14P_ShcP and E14P_ShcP_GS in EGFR/ErbB4 heterodimer-mediated pathways,
respectively. The colors of the graphs indicate activity (% of total protein).
doi:10.1371/journal.pone.0001782.g009
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Materials
Recombinant human epidermal growth factor (EGF) was
purchased from PeproTech House (London, England). Antibodies
for detecting phospho-p44/42 ERK, ERK phospho-MEK and
MEK were purchased from Cell Signaling Technology, Inc.
(Beverly, MA). Anti-EGFR receptor, anti-ErbB4 receptor, anti-
Rap1, anti-Raf and anti-phosphotyrosine (PY20) antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
Ras antibody was purchased from BD Biosciences (San Jose,
USA). GST-Ral GDS-Rap binding domain (RDB) agarose, Raf-
Ras binding domain (RDB) agarose, anti-Shc, and anti-phospho-
Shc (Tyr317) antibodies were purchased from Upstate Biotech-
nology (Lake Placid, NY). U73122 (PLCc inhibitor) and U0126
(MEK inhibitor) were obtained from Calbiochem (San Diego,
CA). Methods for constructing Chinese hamster ovary (CHO) cells
expressing full-length human EGFR and both EGFR and ErbB4
receptors are described elsewhere [21,44].
Cell Culture
CHO cells expressing EGFR or EGFR and ErbB4 receptors
were routinely maintained in DMEM/F12 (Gibco BRL, Githers-
burg, MD) medium supplemented with 10% bovine calf serum
and antibiotics. For detection of the effect of growth hormones, the
cells were starved in serum-free DMEM/F12 for 16–24 hours
prior to the experiment. To test the effect of kinase and
phosphatase inhibitors, the cells were pretreated with the
inhibitors 10 min prior to the addition of EGF. The concentration
of EGF for cell treatments is 10 nM unless otherwise indicated.
Western Blot Analysis
The protein-protein interactions and protein phosphorylation
levels were measured by Western blot analysis. For protein-protein
interaction or receptor phosphorylation analysis, proteins were
immunoprecipitated with corresponding antibodies and immuno-
blotted with antibodies for their interacting proteins or anti-
phosphotyrosine antibody. We examined ERK phosphorylation as
a downstream marker of the MAPK cascade. We used Raf-RDB
andaRap1pull-downassayasactivationmarkersforRasandRap1,
respectively, as described earlier [21]. The band intensities of
proteins were quantified using a densitometer (Fuji Film Corp,
Tokyo, Japan) and normalized by dividing the signal intensity at
each time point by the control at 0 min, and then subtracting 1.0
from these values (Table S1), thus generating normalized data with
no units. For the B-Raf kinase assay, E1/4 cells were treated with
10 nM EGF for 1, 2, 5, 10 and 30 min. Cell lysate was
immunoprecipitated (IP) with an anti-B-Raf antibody and incubated
with a MEK substrate. MEK phosphorylation was examined with
an antibody against phospho-(Ser218/222) MEK1 and phospho-
(Ser222/226) MEK2 followed by densitometric quantification.
Construction of the Raf-MEK-ERK cascade model
The model was constructed on the basis of observations made in
earlier studies. Raf-1 activity is promoted by the association with
an activated form of Ras-GTP (step 1 in Figure 2) and reduced by
phosphorylation on Ser
259 (step 2) [45,46]. B-Raf can be activated
through PLCc and subsequent small GTPase Rap1 (step 3)
[37,41]. MEK is directly activated by Raf-1 and B-Raf (steps 5 and
6) [31], and then doubly phosphorylates ERK (steps 8 and 9)
[25,28]. The MAPK cascade can be negatively modulated by
protein phosphatase 2A (PP2A) through dephosphorylation of
MEK (step 7) and by MAPK phosphatase 3 (MKP3) through
dephosphorylation of ERK (steps 10 and 11) [47,48]. Steps 12–19
were prepared as possible connections regarding feedback/cross-
talk regulations.
Procedure of model selection based on parameter
estimation
For each of the 29 candidate structures, we initially performed
three rounds of parameter estimation whilst changing the starting
points for the parameter search. As an estimator, we used the
genetic algorithm GLSDC [49]. The error equation that is
optimized by GLSDC, ERR, was defined by the total sum of
squares relating the gap between the experimental data and
simulated values at each time point as follows:
ERR~
X
Cell Type
[ E1,E1=4 fg
X
Protein
[P
X
Data Point
[D
Experimental data ð
{Simulated valueÞ
2 ð1Þ
where the sets P={p-ERK, p-MEK} and D are obtained from
Table S1 (nos. 1 and 2). Additionally, we imposed a quantitative
effect relating to U0126 for each candidate as a constraint on the
estimator. U0126 is an irreversible inhibitor of MEK and
functionally lowers the maximum velocity of this enzyme. We set
the velocity (steps 8 and 9 in Figure 2) to 0 to represent complete
inhibition. Then the peak level of simulated MEK activation with
V8=V9=0 should be lower than that of the experimental data with
U0126 (Table S1, no. 3). The following constraints were therefore
imposed during estimation for E1 and E1/4 cells, respectively:
max
t[ 0,1,2,3,
5,10,30
no p{MEKMod
E1 t ðÞwith V8~V9~0
  
v
max
t[ 0,1,2,3,
5,10,30
no p{MEK
Exp
E1 t ðÞwith U0126
   ð2Þ
max
t[ 0,1,2,3,
5,10,30
no p{MEKMod
E1=4 t ðÞwith V8~V9~0
  
v
max
t[ 0,1,2,3,
5,10,30
no p{MEK
Exp
E1=4 t ðÞwith U0126
   ð3Þ
Withthissetting,thetotalconcentrationofeachproteinequalsunity.
We assumed that all proteins are inactive prior to EGF simulation.
We then evaluated each of the estimated parameters using the
quantitative criteria (1)–(3) as outlined below, and selected one that
satisfied most of the criteria of the three trials. If the number of
satisfied criteria was identical, one that yielded the smallest
estimation error was selected. The criteria for model selection were
defined as follows:
(1) Estimation error
For each data point M D
Experimental data{Simulated value jj ƒDE ð4Þ
where
DE~max
D
Experimental data ðÞ |0:25 ð5Þ
Set D is obtained from Table S1 (nos. 1 and 2). The 25% of the
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model describes topological regulation rather than detailed
molecular mechanism, and might not result in perfect fitting.
(2) Effect of U0126 (the inequalities (2) and (3))
(3) Sustained B-Raf activation in E1/4 cells
DUR§1000 sec ðÞ ð 6Þ
where DUR represents the duration time calculated from the time-
course data generated using the model for E1/4 cells, and defined
by
DUR~te{ts ð7Þ
ts represents that time point at which B-Raf activity exceeds 70%
of the maximum activity, and te represents that time point after ts at
which B-Raf activity becomes lower than 70% of the maximum
activity. If DUR values are present due to oscillatory behavior, the
maximum one is used. From the experimental results, the
threshold was set to 1000 sec (Table S1, no. 6).
Parameter estimation of upstream model
The error equation inGLSDC wasdefined byEq. (1) with P={p-
EGFR, p-Shc, Ras-GTP, p-ErbB4} and D as shown in Table S1
(nos. 4, 8–10). The search range for an estimated parameter was
limited within a neighbor of the corresponding value provided in the
earlier study [26] (Table S9). Additionally, we assumed that the
parameter values associated with step nos. 1–12 were identical for
E1 and E1/4 cells. Since ShcP-GS bound to EGFR regulates Ras
activation in both step nos. 12 and 22, the parameter value of step
no. 22 was considered to be identical to that of step no. 12 for
simplicity, although the kinetic parameter might not be necessarily
thesamegiventhedifferentdimerpartners(EGFRorErbB4).Useof
these constraints facilitated selection during the course of the fitting.
Under these conditions, we performed ten rounds of parameter
estimation to reproduce the experimental data (Table 1, nos. 4, 8–
10) since the upstream model seemed to be more complex than the
topological Raf-MEK-ERK model. Finally, the parameter that
yielded the smallest estimation error was selected.
Model Development
To describe the biochemical reactions and connectivity of
signaling molecules in this study, we adopted a deterministic
ordinary differential equation (ODE) model. This methodology
has been employed in many studies using the law of mass action and
the Michaelis-Menten equation [24,26,29,42]. The model was
created to reproduce the normalized experimental data mentioned
in Materials and Methods and was implemented with MATLAB 5.1
(The Mathworks, Inc.) on an AMD Opteron 2.2GHz workstation
running SuSE Linux Enterprise Server 9 (Novell). The MATLAB
function ‘‘ode15s’’ was applied to solve the ODE (http://www.
mathworks.com/ access/helpdesk/help/techdoc/ref/ode15s.html).
All code is available upon request. As a model parameter estimator,
we used the genetic algorithm GLSDC [49]. The program was run
on the RIKEN Super Combined Cluster (RSCC) system.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0001782.s001 (0.03 MB
DOC)
Table S1
Found at: doi:10.1371/journal.pone.0001782.s002 (0.03 MBXLS)
Table S2
Found at: doi:10.1371/journal.pone.0001782.s003 (0.02 MBXLS)
Table S3
Found at: doi:10.1371/journal.pone.0001782.s004 (0.02 MBXLS)
Table S4
Found at: doi:10.1371/journal.pone.0001782.s005 (0.03 MBXLS)
Table S5
Found at: doi:10.1371/journal.pone.0001782.s006 (0.02 MBXLS)
Table S6
Found at: doi:10.1371/journal.pone.0001782.s007 (0.02 MBXLS)
Table S7
Found at: doi:10.1371/journal.pone.0001782.s008 (0.02 MBXLS)
Table S8
Found at: doi:10.1371/journal.pone.0001782.s009 (0.02 MBXLS)
Table S9
Found at: doi:10.1371/journal.pone.0001782.s010 (0.03 MBXLS)
Figure S1 The effect of MEK inhibitor U0126 on ERK
phosphorylation in E1 and E1/4 cells. Serum-starved E1 and
E1/4 cells were incubated with 10 nM EGF for the indicated time
period with or without pretreatment of 200 nM U0126. ERK
phosphorylation was analyzed by Western blot with the corre-
sponding anti-phospho-specific ERK antibodies (upper panel), and
then reblotted with an anti-ERK antibody (lower panel). (A)
Western blot for E1 cells. (B) Western blot for E1/4 cells. Data
show a representative figure of three independent experiments.
Found at: doi:10.1371/journal.pone.0001782.s011 (1.67 MB TIF)
Figure S2 Transfer function model of the signaling pathways.
(A) The substrate S is activated by Eact and deactivated by Edeact.
The activator Eact and deactivator Edeact can be indirectly
activated by ligand. (B) Figure shows a practical example of (A).
When the substrate S is Raf-1, the activator Eact corresponds to
Ras-GTP that is indirectly activated by EGF through some
signaling molecules such as Shc, Grb2, and SOS. (C) The
intermediate reactions between L and Eact (Edeact) are approxi-
mated by the first-order transfer function with the time constant
T1 (T2) and the system gain G1 (G2).
Found at: doi:10.1371/journal.pone.0001782.s012 (0.72 MB TIF)
Figure S3 Model of input signal generator for Ras- and Rap1-
GTPs.Theinputsignalgeneratorreproducesthetime-coursedataof
Ras- and Rap1-GTPs with 10 nM EGF. The model is constructed
with eight transfer functions (steps 20–27). The outputs of the
transfer functions regulate the activity of S1,S 2,S 3 and S4,w h i c ha r e
activators or deactivators for Ras and Rap1 (steps 28–35). Ras and
Rap1 activity is then regulated by those components (steps 36–39).
The symbols are summarized in Table S2. Numbers shown
correspond to the kinetic equations in Table S3.
Found at: doi:10.1371/journal.pone.0001782.s013 (0.61 MB TIF)
Figure S4 Fitting results of the 29 structures. This Figure
contains 2964 figures where row corresponds to a structure
number, and column activated proteins. Blue and red lines
(markers) indicate simulation (experimental) results of E1 and E1/
4 cells, respectively. If a structure satisfied criteria (1)–(3) of the
main text, the word ‘‘pass’’ was put on the upper side of each
figure, otherwise ‘‘fail’’ was put on there. Error bar indicates the
upper and lower bounds calculated from criterion (1) of the main
text. A value on the upper side of a figure in column 4 shows the
duration time. Green and magenta colors mean ‘‘pass’’ and ‘‘fail’’,
Analysis of MAPK Cascade
PLoS ONE | www.plosone.org 12 2008 | Volume 3 | Issue 3 | e1782respectively. The x- and y-axes represent time (min) and activation
(% of total protein), respectively.
Found at: doi:10.1371/journal.pone.0001782.s014 (0.34 MB PDF)
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